Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
Revance Therapeutics, Inc. (RVNC) had Debt to Capital Ratio of 1.30 for the most recently reported fiscal quarter, ending 2024-03-31.
| Income Statement Financials | |
$51.94M |
|
$-53.15M |
|
$14.91M |
|
$37.02M |
|
$98.76M |
|
$-46.83M |
|
$-2.70M |
|
$-49.52M |
|
$-49.52M |
|
$-49.52M |
|
$-49.52M |
|
$-53.15M |
|
$-49.52M |
|
$-46.83M |
|
$-45.45M |
|
91.92M |
|
91.92M |
|
$-0.58 |
|
$-0.58 |
|
| Balance Sheet Financials | |
$369.69M |
|
$17.50M |
|
$138.43M |
|
$508.12M |
|
$68.90M |
|
$424.84M |
|
$537.89M |
|
$606.79M |
|
$-98.67M |
|
$-107.40M |
|
$-98.67M |
|
104.41M |
|
| Cash Flow Statement Financials | |
$-65.94M |
|
$-31.71M |
|
$92.83M |
|
$144.75M |
|
$139.93M |
|
$-4.82M |
|
$8.99M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.37 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
1.30 |
-4.36 |
|
71.29% |
|
-90.16% |
|
-90.16% |
|
-- |
|
-95.36% |
|
-102.34% |
|
$-67.65M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
0.30 |
|
1.74 |
|
51.79 |
|
50.19% |
|
46.11% |
|
-9.75% |
|
-15.18% |
|
$-0.95 |
|
$-0.74 |
|
$-0.72 |
|